Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults

Katia J. Bruxvoort, Bradley Ackerson, Lina S. Sy, Amit Bhavsar, Hung Fu Tseng, Ana Florea, Yi Luo, Yun Tian, Zendi Solano, Robyn Widenmaier, Meng Shi, Robbert Van Der Most, Johannes Eberhard Schmidt, Jasur Danier, Thomas Breuer, Lei Qian
doi: https://doi.org/10.1101/2021.10.01.21264400
Katia J. Bruxvoort
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
2Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35233, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kbruxvoort@uab.edu
Bradley Ackerson
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina S. Sy
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bhavsar
3GSK, 20 Avenue Fleming, 1300 Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hung Fu Tseng
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
4Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Florea
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Luo
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yun Tian
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zendi Solano
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robyn Widenmaier
5GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meng Shi
5GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robbert Van Der Most
6GSK, 89 Rue de l’Institut, 1330 Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Eberhard Schmidt
7GSK, 1 Via Fiorentina, 53100 Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasur Danier
5GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Breuer
3GSK, 20 Avenue Fleming, 1300 Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Qian
1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Vaccines may elicit long-term boosting of innate immune responses that can help protect against COVID-19. We evaluated the association between recombinant adjuvanted zoster vaccine (RZV) and COVID-19 outcomes at Kaiser Permanente Southern California.

Methods In a cohort design, adults aged ≥50 years who received ≥1 RZV dose prior to 3/1/2020 were matched 1:2 to unvaccinated individuals and followed until 12/31/2020. Adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for COVID-19 outcomes were estimated using Cox proportional hazards regression. In a test-negative design, cases had a positive SARS-CoV-2 test and controls had only negative tests, from 3/1/2020-12/31/2020. Adjusted odds ratios (aOR) and 95% CIs for prior receipt of RZV were estimated using logistic regression.

Results In the cohort design, 149,244 RZV recipients were matched to 298,488 unvaccinated individuals. The aHRs (95% CI) for COVID-19 diagnosis and hospitalization were 0.84 (0.81-0.87) and 0.68 (0.64-0.74), respectively. In the test-negative design, 8.4% of 75,726 test-positive cases and 13.1% of 340,898 test-negative controls had received ≥1 RZV dose. The aOR (95% CI) was 0.84 (0.81-0.86).

Conclusion RZV vaccination was associated with a 16% lower risk of COVID-19 diagnosis and 32% lower risk of hospitalization, suggesting RZV elicits heterologous protection, possibly through trained immunity.

Competing Interest Statement

Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Solano, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from the GSK group of companies for work related to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Qian, Ms. Solano, and Ms. Sy received research funding from Dynavax for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Luo, Ms. Sy, and Dr. Tseng received research funding from Seqirus for work unrelated to this paper. Dr. Bruxvoort, Dr. Florea, and Ms. Solano received research funding from Gilead for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from Moderna for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, and Dr. Florea received research funding from Pfizer for work unrelated to this paper. KPSC received fees for consultation work with Johnson and Johnson by Dr. Tseng. Dr. Bhavsar, Ms. Widenmaier, Mr. Shi, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer were employees of the GSK group of companies at the time of the study conduct. Ms. Widenmaier, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer hold shares in the GSK group of companies. All authors do not have any non-financial relationships and activities to declare. This work was supported by GlaxoSmithKline Biologicals SA. Costs associated with manuscript editorial and coordination support were covered by GlaxoSmithKline Biologicals SA. The authors thank the members of Kaiser Permanente for helping to improve care through the use of information collected through our electronic health record systems. Editorial and coordination support was provided by Adrian Kremer (Modis c/o GSK).

Clinical Trial

This is a non-interventional observational trial that has been registered on the GSK-registry trial posting

Funding Statement

This work was supported by GlaxoSmithKline Biologicals SA. Costs associated with manuscript editorial and coordination support were covered by GlaxoSmithKline Biologicals SA. The authors thank the members of Kaiser Permanente for helping to improve care through the use of information collected through our electronic health record systems. Editorial and coordination support was provided by Adrian Kremer (Modis c/o GSK).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Kaiser Permanente Southern California (KPSC) Institutional Review Board reviewed and approved the study with a waiver for the requirement of informed consent

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Solano, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from the GSK group of companies for work related to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Qian, Ms. Solano, and Ms. Sy received research funding from Dynavax for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Luo, Ms. Sy, and Dr. Tseng received research funding from Seqirus for work unrelated to this paper. Dr. Bruxvoort, Dr. Florea, and Ms. Solano received research funding from Gilead for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from Moderna for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, and Dr. Florea received research funding from Pfizer for work unrelated to this paper. KPSC received consultation fees for Dr. Tseng’s consultation work with Johnson and Johnson. Dr. Bhavsar, Ms. Widenmaier, Mr. Shi, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer were employees of the GSK group of companies at the time of the study conduct. Ms. Widenmaier, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer hold shares in the GSK group of companies. All authors do not have any non-financial relationships and activities to declare.

  • This work was supported by GlaxoSmithKline Biologicals SA. Costs associated with manuscript editorial and coordination support were covered by GlaxoSmithKline Biologicals SA.

Data Availability

The study details (GSK study number 217021) are available on the GSK Clinical Study Register and can be accessed at www.gskclinicalstudyregister.com.

https://www.gsk-studyregister.com/en/trial-details/?id=217021

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 03, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults
Katia J. Bruxvoort, Bradley Ackerson, Lina S. Sy, Amit Bhavsar, Hung Fu Tseng, Ana Florea, Yi Luo, Yun Tian, Zendi Solano, Robyn Widenmaier, Meng Shi, Robbert Van Der Most, Johannes Eberhard Schmidt, Jasur Danier, Thomas Breuer, Lei Qian
medRxiv 2021.10.01.21264400; doi: https://doi.org/10.1101/2021.10.01.21264400
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults
Katia J. Bruxvoort, Bradley Ackerson, Lina S. Sy, Amit Bhavsar, Hung Fu Tseng, Ana Florea, Yi Luo, Yun Tian, Zendi Solano, Robyn Widenmaier, Meng Shi, Robbert Van Der Most, Johannes Eberhard Schmidt, Jasur Danier, Thomas Breuer, Lei Qian
medRxiv 2021.10.01.21264400; doi: https://doi.org/10.1101/2021.10.01.21264400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (526)
  • Epidemiology (9990)
  • Forensic Medicine (5)
  • Gastroenterology (496)
  • Genetic and Genomic Medicine (2430)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1632)
  • Health Policy (750)
  • Health Systems and Quality Improvement (632)
  • Hematology (247)
  • HIV/AIDS (528)
  • Infectious Diseases (except HIV/AIDS) (11840)
  • Intensive Care and Critical Care Medicine (623)
  • Medical Education (250)
  • Medical Ethics (73)
  • Nephrology (267)
  • Neurology (2266)
  • Nursing (139)
  • Nutrition (348)
  • Obstetrics and Gynecology (449)
  • Occupational and Environmental Health (532)
  • Oncology (1241)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (727)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (280)
  • Psychiatry and Clinical Psychology (2272)
  • Public and Global Health (4814)
  • Radiology and Imaging (832)
  • Rehabilitation Medicine and Physical Therapy (486)
  • Respiratory Medicine (649)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (123)
  • Urology (99)